Free Trial
NASDAQ:THAR

Tharimmune Q3 2023 Earnings Report

Tharimmune logo
$5.95 -0.10 (-1.65%)
Closing price 04:00 PM Eastern
Extended Trading
$5.85 -0.10 (-1.66%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tharimmune EPS Results

Actual EPS
-$41.25
Consensus EPS
-$18.75
Beat/Miss
Missed by -$22.50
One Year Ago EPS
N/A

Tharimmune Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tharimmune Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
7:00AM ET

Earnings Documents

Tharimmune Earnings Headlines

Biotech Stocks To Watch Today - August 25th
Tharimmune (THUR) Tumbles 20.7% on $5-Million Share Sale
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
Tharimmune Shares Drop After Securities Purchase Agreement
See More Tharimmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tharimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tharimmune and other key companies, straight to your email.

About Tharimmune

Tharimmune (NASDAQ:THAR), a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

View Tharimmune Profile

More Earnings Resources from MarketBeat